Teva Pharmaceutical Industries Limited

DB:TEV Stock Report

Market Cap: €24.4b

Teva Pharmaceutical Industries Past Earnings Performance

Past criteria checks 0/6

Teva Pharmaceutical Industries has been growing earnings at an average annual rate of 17.9%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 1.5% per year.

Key information

17.9%

Earnings growth rate

18.6%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate-1.5%
Return on equity-19.1%
Net Margin-5.7%
Next Earnings Update29 Jan 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Teva Pharmaceutical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:TEV Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2416,772-9593,652978
30 Jun 2416,290-4533,573991
31 Mar 2416,004-4783,542961
31 Dec 2315,846-5593,498953
30 Sep 2315,273-2,3363,433936
30 Jun 2315,017-2,3503,409858
31 Mar 2314,925-1,7113,407847
31 Dec 2214,925-2,4463,445838
30 Sep 2215,141-1,2913,516872
30 Jun 2215,433-1,0543,583919
31 Mar 2215,557-6153,533938
31 Dec 2115,8784173,528967
30 Sep 2116,2317263,6301,016
30 Jun 2116,324-3,9153,6261,052
31 Mar 2116,284-3,9823,6291,030
31 Dec 2016,659-3,9903,671997
30 Sep 2016,673-4,0313,686936
30 Jun 2016,78843,681919
31 Mar 2017,095-8253,783970
31 Dec 1916,887-9993,8061,010
30 Sep 1916,396-4,0483,9221,073
30 Jun 1916,831-4,0074,0511,143
31 Mar 1917,355-3,5594,0871,157
31 Dec 1818,271-2,3994,2141,213
30 Sep 1819,693-11,0594,0731,264
30 Jun 1820,781-10,2564,2801,484
31 Mar 1821,800-16,0504,5891,663
31 Dec 1721,853-16,5254,8461,778
30 Sep 1723,479-5,9635,3352,116
30 Jun 1723,425-6,1455,3702,248
31 Mar 1722,743785,3262,154
31 Dec 1621,903684,9732,077
30 Sep 1620,2921,5914,8631,873
30 Jun 1619,5521,3464,7091,571
31 Mar 1619,4801,6974,6311,582
31 Dec 1519,6521,5734,8381,525
30 Sep 1519,9391,7754,8361,458
30 Jun 1520,1742,5484,9831,509
31 Mar 1520,2532,7575,0211,467
31 Dec 1420,2723,0555,0781,488
30 Sep 1420,5342,7485,2001,520
30 Jun 1420,5352,5835,2251,456
31 Mar 1420,4141,3835,3031,451
31 Dec 1320,3141,2695,3191,427

Quality Earnings: TEV is currently unprofitable.

Growing Profit Margin: TEV is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: TEV is unprofitable, but has reduced losses over the past 5 years at a rate of 17.9% per year.

Accelerating Growth: Unable to compare TEV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TEV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).

Return on Equity

High ROE: TEV has a negative Return on Equity (-19.06%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 23:09
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Teva Pharmaceutical Industries Limited is covered by 60 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Richard SilverBarclays
Balaji PrasadBarclays